When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will present at TD Cowen’s 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA. Presentation Details: Date: Tuesday, March 3, ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Market Overview - U.S. stock futures rose on Friday after a decline on Thursday, with all major benchmark indices showing positive futures [1] - Wall Street is anticipating the release of fourth-quarter GDP data and the Federal Reserve's preferred inflation gauge, the Personal Consumption Expenditure Price Index [1] Treasury Bonds - The 10-year Treasury bond yielded 4.07%, while the two-year bond was at 3.47% [2] - The CME Group's FedWatch tool indicates a 94% likelihood of the Federal Reserve maintaining current interest rates in March [2] Index Performance - Dow Jones increased by 0.26%, S&P 500 by 0.37%, Nasdaq 100 by 0.47%, and Russell 2000 by 0.34% [3] Stocks in Focus - Copart Inc. (NASDAQ: CPRT) dropped 6.64% after reporting quarterly earnings of 36 cents per share, missing the consensus estimate of 40 cents [6] - Comfort Systems USA Inc. (NYSE: FIX) rose 4.57% after better-than-expected fourth-quarter results and an increase in its quarterly dividend [6] - Candel Therapeutics Inc. (NASDAQ: CADL) declined 12.27% following a $100 million public stock offering [7] Sector Performance - Utilities led gains with a 1.13% increase, while Financials experienced the steepest decline, dropping 0.86% [8] Analyst Insights - Scott Wren from Wells Fargo Investment Institute has upgraded the GDP growth forecast to 2.9% from 2.4%, maintaining a bullish outlook on the U.S. economy [9] - Wren recommends focusing on sectors sensitive to growth, specifically Financials and Industrials, which are expected to benefit from AI infrastructure developments [10] - Wren views market pullbacks as opportunities for investment in large- and mid-cap domestic equities, rejecting a defensive positioning strategy [10]

Market Overview - U.S. stock futures rose on Friday after a decline on Thursday, with all major benchmark indices showing positive futures [1] - Wall Street is anticipating the release of fourth-quarter GDP data and the Federal Reserve's preferred inflation gauge, the Personal Consumption Expenditure Price Index [1] Treasury Bonds - The 10-year Treasury bond yielded 4.07%, while the two-year bond was at 3.47% [2] - The CME Group's FedWatch tool indicates a 94% likelihood that the Federal Reserve will keep interest rates unchanged in March [2] Index Performance - Dow Jones increased by 0.26%, S&P 500 by 0.37%, Nasdaq 100 by 0.47%, and Russell 2000 by 0.34% [3] Company Performance - Copart Inc. (NASDAQ: CPRT) dropped 6.64% after reporting quarterly earnings of 36 cents per share, missing the consensus estimate of 40 cents [6] - Comfort Systems USA Inc. (NYSE: FIX) rose 4.57% after better-than-expected fourth-quarter results and an increase in its quarterly dividend [6] - Candel Therapeutics Inc. (NASDAQ: CADL) declined 12.27% following the announcement of a $100 million public stock offering [7] Sector Insights - Utilities led gains with a 1.13% increase, while Financials experienced the steepest decline, dropping 0.86% [8] Analyst Insights - Scott Wren from Wells Fargo Investment Institute has upgraded the GDP growth forecast to 2.9% from 2.4%, maintaining a bullish outlook on the U.S. economy [9] - Wren recommends focusing on sectors sensitive to growth, specifically Financials and Industrials, which are expected to benefit from AI infrastructure developments [10] - Wren views market pullbacks as opportunities to invest in large- and mid-cap domestic equities rather than retreating into defensive assets [10] Upcoming Economic Data - Key economic data to be released includes fourth-quarter GDP, personal income, spending, and PCE data, along with February's S&P flash U.S. services and manufacturing PMI [13]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $100 million of its common stock. Candel also intends to grant the underwriters a 30-day option to purchase up to an additional $15 million in shares of its common stock on the same terms and condi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 CANDEL THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 117 Kendrick St Suite 450 Needham, Massachusetts 02494 (Address of Principal Executive Offices) (Zip Code) Delaware 001-40629 52-2214851 (Commission ...

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized prostate cancer                   Royalties based on annual net sales of aglatimagene in the U.S.Funds will strengthen the Company’s balance sheet for potential U.S. commercial launch of aglatimagene in intermediate- to high-risk localized prostate cancer NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel ...

Core Insights - Candel Therapeutics, Inc. is focused on developing multimodal biological immunotherapies for cancer treatment and will present at the 7th Annual Glioblastoma Drug Development Summit in February 2026 [1] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses [4] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] - The lead product candidate from the adenovirus platform is aglatimagene besadenovec (CAN-2409), which has completed successful phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is undergoing a pivotal phase 3 trial in localized prostate cancer [4] Product Development - Linoserpaturev (CAN-3110) is the lead candidate from the HSV platform, currently in a phase 1b clinical trial for recurrent high-grade glioma [5] - In October 2023, results from a clinical trial indicated that linoserpaturev was well tolerated with no dose-limiting toxicity, showing improved median overall survival compared to historical controls after a single injection [3] - The company is supported by the Break Through Cancer foundation to evaluate repeated linoserpaturev injections in patients with recurrent glioblastoma [3] Upcoming Presentations - Dr. Francesca Barone will present insights on Candel's HSV-based platform and the linoserpaturev program at the summit, including a workshop on patient stratification and a conference presentation on integrating biomarkers and imaging [2][3]